Growth Hormone Therapy: Every Question Parents Ask

Key signs include growing less than 2 inches per year after age 3, consistently below the 3rd percentile on growth charts, a significant drop across percentile lines over time, delayed puberty, or a confirmed or suspected diagnosis of growth hormone deficiency. Only a physician evaluation can determine whether your child qualifies. See our full guide: Does My Child Need Growth Hormone?

The younger, the better. Once growth plates close permanently in the mid-to-late teenage years, no medication can increase height. Starting earlier means more time to benefit and greater potential height gain. Children from approximately age 3 through late adolescence can be evaluated, as long as growth plates remain open.

FDA-approved indications include: Growth Hormone Deficiency (GHD), Idiopathic Short Stature (ISS), Small for Gestational Age (SGA) without catch-up growth, Turner Syndrome, Prader-Willi Syndrome, Noonan Syndrome, and chronic kidney disease. A physician determines eligibility after comprehensive evaluation.

Growth Hormone Deficiency (GHD) is a confirmed pituitary condition where insufficient GH is produced, verified through stimulation testing. Idiopathic Short Stature (ISS) refers to significant short stature with no identifiable cause and normal GH levels. Both are FDA-approved indications for therapy. See: GHD Overview and ISS Overview.

General pediatricians are not growth specialists. If you have persistent concerns — especially if your child is consistently below the 3rd percentile, crossing percentile lines downward, or growing less than 2 inches per year — a consultation with a specialist is reasonable. Our free telemedicine consultation gives you an informed second perspective at no cost.

Yes. Constitutional growth delay (being a "late bloomer") and familial short stature (short parents) are the most common reasons a child is shorter than peers without a qualifying medical diagnosis. A physician evaluation is the only way to distinguish between these patterns and conditions that may benefit from therapy.

The comprehensive initial evaluation (physician exam + intake labs) is approximately $2,000. Monthly medication costs range from $2,000 to $5,000 depending on the child's weight, diagnosis, and prescribed protocol. See our full Cost Guide.

Our partner clinics are cash-pay only. Insurance is not accepted. Treatment is entirely out-of-pocket. This is a deliberate choice that enables faster access, no prior authorization delays, and no insurance denials based on policy criteria rather than medical need.

Yes, in most cases. Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) are generally eligible for physician-prescribed medical treatments. Consult your plan administrator to confirm eligibility and any documentation requirements before your appointment.

Most children require several years of treatment. At $2,000–$5,000 per month, the annual medication cost ranges from $24,000–$60,000. A child starting at age 7 and treating through age 13 would have an estimated total medication cost of $144,000–$360,000, plus the initial $2,000 evaluation. This is a significant financial commitment — we encourage every family to have a complete cost discussion before proceeding.

Growth hormone therapy has been FDA-approved for children since 1985. Large post-marketing safety registries tracking over 83,000 patients have not demonstrated increased cancer risk in healthy children. Common side effects are mild. Serious side effects are uncommon and actively monitored. See our full Side Effects Guide.

This is the most common parental concern. The KIGS registry (83,000+ patients) has not demonstrated increased new cancer development in children without pre-existing risk factors. Children with a prior cancer history are not candidates for GH therapy. Current Pediatric Endocrine Society guidelines do not identify cancer as an elevated risk in otherwise healthy pediatric patients.

Most common: injection site soreness, mild headache during initiation, and temporary fluid retention. Less common but monitored: slipped capital femoral epiphysis (hip pain — report immediately), intracranial hypertension (severe headache), and changes in blood glucose. Regular physician monitoring is built into treatment specifically to catch these early.

Clinical studies do not support the concern that GH therapy inappropriately accelerates puberty in children treated for GHD or ISS. Bone maturation is monitored throughout treatment via regular bone age X-rays.

Missing an occasional injection has minimal clinical impact. Do not double-dose to compensate. Follow the physician's protocol for missed doses. Consistency over time matters more than any single injection. If injections are being missed frequently, discuss this with the physician — it affects treatment efficacy and dose planning.

Results vary by diagnosis and age. Children with GHD often achieve near-normal adult height — significant gains are typical. Children with ISS gain an average of 1–3 additional inches of adult height. Earlier treatment start and younger age at initiation are associated with greater gains.

Most children show measurable accelerated growth within 3–6 months. The first year typically produces the most dramatic response — often 8–10 cm of growth. Growth velocity is measured at every follow-up visit to confirm treatment response.

Response to therapy is monitored closely. If a child is not responding adequately — defined by insufficient growth velocity improvement after 6–12 months — the physician will evaluate reasons including dose adequacy, compliance, and whether an alternative diagnosis may be present. Treatment may be adjusted, changed, or discontinued based on clinical response.

Most children continue treatment until growth plates close, typically in the mid-to-late teenage years. Bone age X-rays track growth plate status throughout treatment. The physician will advise when growth plate closure is approaching and plan treatment transition accordingly.

Request a complimentary 20-minute telemedicine consultation at hghkids.com/contact/ or call (949) 468-3120. Our care team reviews your child's growth history, answers your questions, and helps determine if a formal evaluation is appropriate. No charge, no obligation.

The initial consultation is via telemedicine — available in all 50 states at no charge. The in-person evaluation (~$2,000) requires one visit to our partner clinic in Irvine, CA. Many families travel from across the country for this one visit. Follow-up appointments can often be done via telemedicine.

The comprehensive evaluation includes: physician exam and medical history review, bone age X-ray, blood hormone panel (IGF-1, IGFBP-3, thyroid), and growth hormone stimulation testing where indicated. Results are typically reviewed with the family shortly after the visit. See: Growth Evaluation Overview.

Typically every 3–6 months, including blood work, height measurement, and clinical review. Bone age X-rays are performed approximately annually. Follow-up frequency may be higher at treatment initiation and during periods of dose adjustment.

All prescriptions and treatment decisions are made by the licensed physicians at our partner clinics — never by HGHKids.com. HGHKids.com is an educational and referral platform. Once connected, your family's care relationship is directly with the physician.